News und Analysen

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio^® (formerly

Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA^® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI^®

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 42^nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9^th, at 10:30 a.m. PST (1:30

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer^® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023. Novocure is a global oncology company

NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity

Agilent Technologies Inc. (NYSE: A) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.

Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the J.P. Morgan Healthcare

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, at The Westin St. Francis, San

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 42^nd Annual J.P. Morgan

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 42nd Annual JPMorgan Healthcare Conference on Monday, January 8, 2024, at approximately 3:00 p.m. PST at the

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Novocure (NASDAQ: NVCR) announced today that management will participate in the 42^nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman

QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can